What is olfactory neuroblastoma?
Olfactory neuroblastoma is a rare cancer that starts high up inside the nose. It grows from the olfactory epithelium, the special lining at the roof of the nasal cavity that contains the nerve cells responsible for the sense of smell.
It is also widely known as esthesioneuroblastoma. The two names mean the same disease.
Despite the similar name, it is not the same as neuroblastoma, the childhood cancer of the adrenal glands and nerves. Olfactory neuroblastoma mostly affects adults, although it can occur at almost any age.
It makes up about 3-6% of cancers of the nose and sinuses. Its position just under the cribriform plate, the thin, sieve-like bone that separates the nose from the brain, is important because the tumour can grow upwards into the skull base and brain or sideways into the eye socket.
Early symptoms, such as a blocked nose and nosebleeds on one side, are easily mistaken for sinusitis or nasal polyps. Diagnosis is therefore often delayed.
With modern surgery and radiotherapy, many people are cured. The cancer can come back many years later, however, so long-term follow-up is essential.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Neuroectodermal cancer of the olfactory (smell) lining |
| How common | About 3-6% of nasal and sinus cancers; roughly 0.4 cases per million people a year |
| Typical age | Any age; most often 40-70 |
| Sex | Men and women about equally |
| Main site | Roof of the nasal cavity, near the cribriform plate |
| Spread | Locally into sinuses, eye socket and brain; neck lymph nodes; rarely distant |
| Main treatments | Surgery followed by radiotherapy; chemotherapy for advanced disease |
| Outlook | About 70-80% alive at 5 years; late recurrences are common |
2. Causes and risk factors
The cause of olfactory neuroblastoma is not known. Unlike some other nasal cancers, it has no clear link with wood dust, smoking or occupational chemicals.
| Factor | What is known |
|---|---|
| Age | Can occur at any age, with most cases in middle age |
| Sex | No strong difference |
| Smoking, wood dust, chemicals | No proven link |
| Inherited conditions | No known inherited syndrome |
| Previous radiation | Rare reports after radiotherapy to the head |
It is not infectious and is not passed on in families.
3. How does it look
Inside the nose
On examination with a thin camera (endoscope), the tumour usually appears as a soft, fleshy, reddish-grey or pink mass high in one side of the nose. It may look like a nasal polyp.
The tumour is often rich in blood vessels, so it may bleed easily when touched. Larger tumours can fill the nasal cavity and push the septum to the other side.
Visible changes on the face
Most early tumours cause no visible change. Larger tumours may cause:
| Sign | Description |
|---|---|
| Bulging eye | One eye pushed forward (proptosis) from tumour in the eye socket |
| Swelling | Fullness between the eyes or over the cheek |
| Watery eye | Constant tearing from blockage of the tear duct |
| Neck lump | A firm, painless swelling from lymph node spread |
On scans
| Scan | What doctors may see |
|---|---|
| CT | A soft-tissue mass at the roof of the nose with thinning or destruction of the cribriform plate and nearby bones |
| MRI | Shows growth through the skull base; a “dumbbell” shape above and below the cribriform plate and small cysts at the brain edge are typical |
| PET-CT or DOTATATE PET | Looks for spread to lymph nodes and distant sites; many tumours take up somatostatin-receptor tracers |
Under the microscope
The pathologist sees lobules of small round blue cells separated by fibrous tissue. The cells often sit in a fine, fibrillary background made of nerve fibres.
Rosettes may be present. These are rings of tumour cells around a central core and are called Homer Wright or Flexner-Wintersteiner rosettes.
| Marker | Typical result |
|---|---|
| Synaptophysin, chromogranin | Positive (nerve-endocrine features) |
| S100 | Positive in supporting cells around the edges of the lobules |
| Cytokeratin | Usually negative or only focal, which helps separate it from carcinomas |
| Ki-67 | Shows how fast cells are dividing |
Hyams grade
The tumour is graded using the Hyams system. Grades I and II are low grade, and grades III and IV are high grade.
| Hyams grade | Features | Behaviour |
|---|---|---|
| I | Well-formed lobules, plenty of fibrillary matrix, little cell division | Slowest growing |
| II | Similar, with slightly more atypia | Low grade |
| III | Less matrix, more cell division, some dead tissue | High grade |
| IV | Little or no matrix, marked atypia, much dead tissue | Most aggressive |
High-grade tumours carry a higher risk of spread and death (Goshtasbi et al., 2019).
4. Symptoms
Symptoms usually develop slowly over months or even years. Because they are so similar to common nasal problems, many people are first treated for sinusitis or allergies.
Common symptoms
- Blocked nose on one side that does not clear; the most common symptom
- Nosebleeds, often from one side and recurring
- Reduced or lost sense of smell (hyposmia or anosmia)
- Runny nose or discharge, sometimes blood-stained
- Headache or pressure over the forehead or between the eyes
- Recurrent sinus infections
Symptoms of more advanced disease
- Bulging eye, double vision or reduced vision
- Watery eye
- A lump in the neck from lymph node spread
- Personality change, seizures or confusion if the tumour grows into the front of the brain
- Clear fluid dripping from the nose if the barrier between the nose and brain is breached
Hormone-related symptoms
Rarely, the tumour produces hormones. It may cause low sodium levels (SIADH), leading to confusion, tiredness and nausea, or Cushing syndrome from ACTH production.
When to see a doctor
See your doctor if you have a blocked nose, nosebleeds or loss of smell on one side that lasts more than 3 weeks. One-sided symptoms that do not respond to usual treatment should be checked with an endoscopic examination by an ear, nose and throat (ENT) specialist.
Olfactory neuroblastoma in children and teenagers
Olfactory neuroblastoma is uncommon in children, but it does occur, mostly in teenagers. Young people often present with larger tumours, partly because nasal symptoms in this age group are usually blamed on colds or allergies.
Children are treated in specialist paediatric centres. Treatment combines surgery, radiotherapy and often chemotherapy, with particular care to limit the effects of radiotherapy on growth, hormones and learning.
5. Diagnosis
| Test | Purpose |
|---|---|
| Nasal endoscopy | Looks directly at the mass inside the nose |
| CT of the sinuses | Shows bone thinning or erosion |
| MRI of the head | Shows spread into the eye socket, skull base and brain |
| Biopsy | Confirms the diagnosis; usually taken under general anaesthetic after imaging |
| Neck ultrasound or MRI | Checks for lymph node spread |
| PET-CT or DOTATATE PET | Looks for distant spread in advanced or high-grade disease |
| Blood sodium and hormone tests | If hormone symptoms are suspected |
Under the microscope, olfactory neuroblastoma must be distinguished from other small round cell tumours of the nose. These include sinonasal undifferentiated carcinoma, neuroendocrine carcinoma, lymphoma, melanoma, rhabdomyosarcoma and Ewing sarcoma.
6. Staging
The most widely used system is the Kadish system (Kadish et al., 1976), later modified by Morita (Morita et al., 1993).
| Kadish stage | Extent of disease |
|---|---|
| A | Limited to the nasal cavity |
| B | Nasal cavity and one or more paranasal sinuses |
| C | Beyond the nose and sinuses: eye socket, skull base, brain or cribriform plate |
| D (modified) | Spread to neck lymph nodes or distant sites |
Most people are diagnosed at stage B or C. A TNM-based system (Dulguerov) is also used in some centres.
7. Treatment
Treatment is planned by a skull base multidisciplinary team, including ENT surgeons, neurosurgeons, radiation oncologists and medical oncologists. Recent French consensus guidelines summarise current practice (Gorzkowski et al., 2026).
Surgery
Surgery to remove the tumour completely with clear margins is the most important treatment.
| Approach | Description |
|---|---|
| Endoscopic endonasal resection | Performed through the nostrils with cameras; now the preferred approach in many centres for suitable tumours |
| Open craniofacial resection | Combines an approach through the skull with one through the face or nose; used for very large tumours |
To achieve clear margins, the surgeon usually removes the cribriform plate, the lining of the brain above it and the olfactory bulb. The skull base is then rebuilt, often using a flap of tissue from the inside of the nose.
Radiotherapy
Radiotherapy after surgery is given to most patients, especially those with stage B or higher, high-grade tumours or close margins. It reduces the risk of local recurrence.
Intensity-modulated radiotherapy (IMRT) or proton beam therapy is used to protect the eyes, optic nerves and brain. Radiotherapy to the neck may be added for advanced tumours, as neck spread is common later.
Chemotherapy
| Situation | Role of chemotherapy |
|---|---|
| Very large tumours | Chemotherapy before surgery (induction) to shrink the tumour, often cisplatin and etoposide |
| High-grade tumours | May be combined with radiotherapy |
| Spread to distant sites | Main treatment, with radiotherapy for symptoms |
| Recurrence | Chemotherapy, further surgery or radiotherapy; somatostatin-targeted treatments are being explored |
Neck lymph nodes
Lymph node spread is present in a small proportion of people at diagnosis, but it can develop years later (Kuan et al., 2019). If nodes are involved, a neck dissection and radiotherapy are performed.
8. Outlook (prognosis)
The outlook for olfactory neuroblastoma is generally good compared with many other skull base cancers. Large studies report 5-year survival of roughly 70-80%, and higher in some modern series (Abdelmeguid et al., 2022).
| Factor | Effect on outlook |
|---|---|
| Kadish stage | Stages A and B do best; stage D has the poorest outlook |
| Hyams grade | Low-grade tumours do much better than high-grade |
| Clear surgical margins | Strongly linked with better control |
| Postoperative radiotherapy | Lowers the risk of local recurrence |
| Neck node spread | Poorer outlook |
A meta-analysis found that grade and lymph node spread were among the strongest predictors of survival (Dulguerov et al., 2001).
Late recurrence
A distinctive feature of olfactory neuroblastoma is its tendency to return many years later, sometimes after 10 years or more. Recurrences may occur at the original site, in the neck or, less often, elsewhere.
For this reason, follow-up usually continues for life or at least 10-15 years.
9. Living with olfactory neuroblastoma
| Concern | What helps |
|---|---|
| Loss of smell | Usually permanent after surgery; fit smoke and gas alarms, check food dates, and label leftovers |
| Taste changes | Flavour depends on smell; experimenting with texture, spices and temperature can help |
| Nasal crusting | Regular saline rinses, especially after surgery and radiotherapy |
| Dry eyes and vision | Eye checks during and after radiotherapy |
| Hormone changes | Radiotherapy near the pituitary gland may affect hormones; yearly blood tests are often advised |
| Emotional effects | Support from specialist nurses, psychologists and head and neck cancer groups |
Follow-up
Follow-up includes nasal endoscopy and MRI of the head and neck. These are usually done every 3-4 months in the first two years, then less often, and continue long term.
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is it the same as childhood neuroblastoma? | No. Despite the similar name, it is a different cancer |
| Will I lose my sense of smell? | Usually yes, as the smell nerves are removed or affected by treatment |
| Do I need brain surgery? | The surgery involves the skull base, but it can often be done through the nose without opening the skull |
| Can it be cured? | Yes, many people are cured, especially with early-stage, low-grade tumours |
| Why is follow-up so long? | Because this cancer can come back many years after treatment |
11. Questions to ask your care team
- What Kadish stage and Hyams grade is my tumour?
- Can it be removed endoscopically through the nose?
- Will I need radiotherapy, and is proton therapy an option?
- Is chemotherapy recommended before or after surgery?
- Will my neck be treated?
- How long will my follow-up last?
Resources
- Kadish, S., Goodman, M. and Wang, C.C. (1976) ‘Olfactory neuroblastoma. A clinical analysis of 17 cases’, Cancer, 37(3), pp. 1571-1576.
- Morita, A. et al. (1993) ‘Esthesioneuroblastoma: prognosis and management’, Neurosurgery, 32(5), pp. 706-714.
- Dulguerov, P., Allal, A.S. and Calcaterra, T.C. (2001) ‘Esthesioneuroblastoma: a meta-analysis and review’, The Lancet Oncology, 2(11), pp. 683-690.
- Goshtasbi, K. et al. (2019) ‘Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis’, International Forum of Allergy and Rhinology, 9(9), pp. 1054-1062.
- Kuan, E.C. et al. (2019) ‘A population-based analysis of nodal metastases in esthesioneuroblastomas of the sinonasal tract’, The Laryngoscope, 129(5), pp. 1025-1029.
- Abdelmeguid, A.S. et al. (2022) ‘Long-term outcomes of olfactory neuroblastoma: MD Anderson Cancer Center experience and review of the literature’, The Laryngoscope, 132(2), pp. 290-297.
- Fiani, B. et al. (2019) ‘Esthesioneuroblastoma: a comprehensive review of diagnosis, management, and current treatment options’, World Neurosurgery, 126, pp. 194-211.
- Gorzkowski, V. et al. (2026) ‘REFCOR guidelines on the management of olfactory neuroblastoma: a formalized expert consensus’, European Annals of Otorhinolaryngology, Head and Neck Diseases, 143(4), pp. 325-329.
- National Cancer Institute (2026) Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/paranasal-sinus-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.